Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00413036
Status:
COMPLETED
Last Update Posted:
2017-03-01
First Post:
2006-12-18
Brief Title:
A Study of Revlimid in the Treatment of Non-Hodgkins Lymphoma
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Multicenter Single-Arm Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide Revlimid CC-5013 in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle Treatment will continue until disease progression or unacceptable adverse events develop
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None